Patton Fills VoIP-Market Gap with SmartNode BRI/FXS/FXO Gateway-Router
Patton's new 8-to-24-call SmartNode 4660 addresses the Euro-market demand for a cost-effective, one-box VoIP-router solution for up to 8-BRIs with multiple FXS/FXO interfaces
SmartNode™ VoIP... more than just talk!
Patton Electronics (www.patton.com )—together with Patton-Inalp Networks —announced today and is now taking orders for the 8-to-24-call SmartNode™ 4660 BRI/FXS/FXO VoIP Gateway Router for mid-sized enterprises and service providers.
With today's announcement Patton addresses the demand for VoIP-enabling solutions in European markets where incumbent PSTNs offer 8-BRI services alongside FXS/FXO lines often supplied by CLECs. Initial shipments are expected during May 2012.
Patton's SN4660 fills the void between high-cost modular VoIP equipment (overkill for most mid-size businesses) and kludgey multi-box solutions (cobbled together from lower-quality, smaller-port-count devices).
Offering flexible port combinations of 2-to-8 ISDN BRIs, a standard 4-port IP-Ethernet switch, and optional 4-to-8 analog FXS/FXO interfaces, the SmartNode 4660 IP-enables ISDN-PBX systems and POTS phone, fax, answering machine, and audio-intercom systems with a cost-effective, one-box solution for 8-to-24 voice or fax calls over IP.
Four 10/100 Ethernet ports provide seamless WAN access via any existing cable, ADSL, VDSL, EFM, or fiber-optic modem, as well as enterprise LAN connectivity.
"We just listened to our customers," said Bernhard Fluehmann, Converged IP Product Manager with Patton-Inalp. "SmartNode users know all about our can-do culture. Patton is focused on meeting real-world needs and delivering on hard requirements for actual projects. That's how the SN4660 came about. Customers asked and Patton delivered."
As a mid-sized enterprise itself, Patton majors on flexible manufacturing combined with responsive product engineering. Since the company houses sales, marketing, engineering and manufacturing—all under one roof—in its US-based bricks-and-mortar headquarters, Patton can respond to market feedback and deliver orders faster than most other VoIP or Telecom equipment suppliers.
During March and April, Patton offers resellers and channel partners promotional discounts ranging from 5 to 20 percent on SN4660 pre-orders, depending on order quantities and timing (contact sales@patton.com for details).
Next-up from Patton and SmartNode... watch for an 8-BRI FXS/FXO VoIP IAD with an on-board G.SHDSL internet-access modem.
In related news, SmartNode recently scored its seventh product-of-the-year award from INTERNET TELEPHONY® magazine, while last month Patton unveiled the SmartNode™ 10200 carrier-grade TDM + VoIP media gateway series, supporting up to 2048 voice or fax calls.
Contact:
Patton Electronics
Glen Flowers, 301-975-1000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom